% | $
Quotes you view appear here for quick access.

Cytokinetics, Incorporated Message Board

  • mirror_world_man mirror_world_man Jul 10, 2013 7:22 PM Flag

    AMGN releases OM commercialization rights to SERVIER in the EU

    Looks like a straightforward trade deal, still I was surprised to read it. Overall I like AMGN as a buddy better than SERVIER. But SERVIER does have strong European marketing experience. Any comments?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • welcome back, have to admit, all these little (and big) deals are catching me off guard. the latest is evidence that amgen is planning on om being a world wide blockbuster and they are setting themselves up to see it through. i am more bullish now than i have ever been on our long term prospects.

      Sentiment: Strong Buy

    • It kind of reminds me of Amgen's start up days, when they sold J&J the international rights to Epogen, their first drug, because Amgen had no international presence. This is Amgen's first cardiac drug.
      What's more important is that it further confirms to me that the OM phase 2 trial was successful. I don't think Servier would have given up US rights to their successful cardiac drug to get OM, if they had not been shown the results of the trial. And Amgen knows the synergistic effects of those two drugs will create a Lipitor-like franchise for them. The insurance companies are desperate for a way to keep the millions of chronic heart failure patients out of the hospital, especially given our demographic future. They will pay up. I have also bought Amgen, because I think they are going to steal CYTK for peanuts.

9.04+0.05(+0.56%)Jun 24 4:00 PMEDT